"Pharmacogenomic Variants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).
| Descriptor ID |
D000071184
|
| MeSH Number(s) |
G05.365.795.446
|
| Concept/Terms |
Pharmacogenomic Variants- Pharmacogenomic Variants
- Pharmacogenomic Variant
- Variant, Pharmacogenomic
- Variants, Pharmacogenomic
- Pharmacokinetic Genetic Variants
- Genetic Variant, Pharmacokinetic
- Genetic Variants, Pharmacokinetic
- Pharmacokinetic Genetic Variant
- Pharmacogenetic Variants
- Pharmacogenetic Variant
- Variant, Pharmacogenetic
- Variants, Pharmacogenetic
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Variants".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Variants".
This graph shows the total number of publications written about "Pharmacogenomic Variants" by people in this website by year, and whether "Pharmacogenomic Variants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 2 | 5 |
| 2017 | 3 | 1 | 4 |
| 2018 | 4 | 1 | 5 |
| 2019 | 3 | 2 | 5 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenomic Variants" by people in Profiles.
-
Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention in Chronic Kidney Disease: a Post Hoc Analysis of the TAILOR-PCI Study. Cardiovasc Drugs Ther. 2024 Jun; 38(3):447-457.
-
Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. Br J Cancer. 2022 03; 126(4):640-651.
-
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 01; 111(1):263-271.
-
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application. Pharmacogenomics J. 2021 12; 21(6):691-711.
-
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020 09; 108(3):625-634.
-
Pharmacogenomic-Based Decision Support to Predict Adherence to Medications. Clin Pharmacol Ther. 2020 08; 108(2):368-376.
-
Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020 03; 579(7798):274-278.
-
Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice. Pharmacogenomics J. 2020 10; 20(5):736-745.
-
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.